
Health News
Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress
05/21/2021
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4),
Read More